Literature DB >> 18066679

Prevalence of the prothrombin G20210A polymorphism in the Lebanese population: use of a reverse hybridization strip assay approach.

Amira S Sabbagh1, Georges Ibrahim, Ziad Kanaan, Dina M R Shammaa, Rabab Abdel Khalek, Mona Ghasham, Layal Greige, Rami A R Mahfouz.   

Abstract

The factor II (prothrombin) G20210A gene polymorphism is the second most common SNP reported in VTE where it is associated with elevated plasma prothrombin levels and with a 3-fold increased risk. We studied the distribution of the G/G, G/A, and A/A genotypes of the Prothrombin G20210A gene mutation in the general Lebanese population using a novel technique in order to assess their prevalence, compare the results to previously reported data and to describe an available method that will permit easy and fast identification of the mutation. Prothrombin different genotypes were determined using the Cardiovascular Disease (CVD) StripAssay which is based on a Polymerase Chain Reaction-Reverse hybridization technique and DNA from 205 unrelated healthy donors from our HLA-bank was used. The prevalence of G/G, G/A, and A/A genotypes was found to be 98.54, 1.46, and 0%, respectively, with G and A allelic frequency of 99 and 1%, respectively. The sampled Lebanese population showed prothrombin genotypes distribution similar to Caucasians, and our results are comparable to other reports on the Lebanese healthy individuals. However, this is the first report on the prevalence of prothrombin G20210A mutation using this technique. Our results suggest that this approach is reliable and can be used as an assessment for thrombophilia profile. In addition, future investigations should be conducted to assess the contribution of the prothrombin G20210A mutation, on its own and in collaboration with other factors, in various clinical entities notably VTE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18066679     DOI: 10.1007/s11033-007-9193-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  40 in total

1.  Born to clot: the European burden.

Authors:  D C Rees; N H Chapman; M T Webster; J F Guerreiro; J Rochette; J B Clegg
Journal:  Br J Haematol       Date:  1999-05       Impact factor: 6.998

2.  Prevalence of the prothrombin G20210A mutation in the Irish populations: use of a novel polymerase chain reaction approach.

Authors:  C Keenan; W J Livingstone; B White; L Mynett-Johnson; S Cusack; M Lawler; O P Smith
Journal:  Blood Coagul Fibrinolysis       Date:  2000-10       Impact factor: 1.276

3.  Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3'-untranslated region of the prothrombin gene.

Authors:  K Brown; R Luddington; D Williamson; P Baker; T Baglin
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

Review 4.  The prothrombin 20210 G to A variation and thrombosis.

Authors:  R M Bertina
Journal:  Curr Opin Hematol       Date:  1998-09       Impact factor: 3.284

5.  A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene.

Authors:  A Zivelin; N Rosenberg; S Faier; N Kornbrot; H Peretz; C Mannhalter; M H Horellou; U Seligsohn
Journal:  Blood       Date:  1998-08-15       Impact factor: 22.113

6.  Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR.

Authors:  M J Lay; C T Wittwer
Journal:  Clin Chem       Date:  1997-12       Impact factor: 8.327

7.  Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria.

Authors:  W Renner; H Köppel; C Hoffmann; K Schallmoser; O Stanger; H Toplak; T C Wascher; E Pilger
Journal:  Thromb Res       Date:  2000-07-01       Impact factor: 3.944

8.  Prothrombin G20210A gene mutation with LightCycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey.

Authors:  Orhan Ayyildiz; Sevgi Kalkanli; Sabri Batun; Mehmet Aybak; Abdurrahman Isikdogan; Naci Tiftik; Zahit Bolaman; Murat Soker; Ekrem Muftuoglu
Journal:  Heart Vessels       Date:  2004-07       Impact factor: 2.037

Review 9.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

10.  Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.

Authors:  T W Kim; W K Kim; J H Lee; S B Kim; S W Kim; C Suh; K H Lee; J S Lee; E J Seo; H S Chi; S H Kim
Journal:  J Korean Med Sci       Date:  1998-12       Impact factor: 2.153

View more
  6 in total

1.  Factor V Leiden, prothrombin 20210G>A, MTHFR 677C>T and 1298A>C, and homocysteinemia in Tunisian blood donors.

Authors:  Samira Hadhri; Mohamed Ben Rejab; Hajer Guedria; Lamia Ifa; Noureddine Chatti; Hadef Skouri
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

2.  Prevalence of H1299R polymorphism in the Factor V gene among the Taif-Saudi Arabia population using polymerase chain reaction-reverse hybridization technique.

Authors:  Nabil Saied Awad; Adel El-Sayed El-Tarras
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

3.  The association between cardiovascular disease gene mutations and recurrent pregnancy loss in the Lebanese population.

Authors:  Hanadi El Achi; Johnny Awwad; Sarah Abou Daya; Sahar Halabi; Sandra Damianos; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2018-07-04       Impact factor: 2.316

4.  Epidemiology of Prothrombin G20210A Mutation in the Mediterranean Region.

Authors:  Mehrez M Jadaon
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-11-28       Impact factor: 2.576

5.  Significance of the use of the ViennaLab "Cardiovascular Disease panel" (CVD) Assay as a reflex test for the "Factor V/II/MTHFR Assay".

Authors:  Rouba Hoteit; Fatmeh Abbas; Ahmad Antar; Rabab Abdel Khalek; Dina Shammaa; Rami Mahfouz
Journal:  Meta Gene       Date:  2013-11-19

6.  Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients?

Authors:  R Kreidy; N Irani-Hakime
Journal:  Vasc Health Risk Manag       Date:  2009-08-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.